Director, Clinical Pharmacology Les Laboratoires Servier SASDirector, Clinical PharmacologyCARemote$200,000–$255,000 / yearThe role involves strong cross-functional collaboration with internal and external partners, including Clinical Operations, Biostatistics, Data Management, Medical Writing, Regulatory, Safety, Technical Operations and regulatory agencies, to advance drug candidates in an efficient and scientifically rigorous manner. Minimum of 8 years of experience working as a clinical pharmacologist in pharmaceutical industry, research institutions and/or regulatory agencies, with a strong track record in designing, interpreting, and reporting clinical pharmacology studies.
Senior Director, Clinical Pharmacology Revolution Medicines IncSenior Director, Clinical PharmacologyRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Work with the Discovery organization to support assets in the IND-enabling stage, including collaboration with DMPK and Toxicology groups in assessment of human start dose and assessment of the need for human DDI studies.
Senior Director, Clinical Pharmacology Revolution MedicinesSenior Director, Clinical PharmacologyRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Work with the Discovery organization to support assets in the IND-enabling stage, including collaboration with DMPK and Toxicology groups in assessment of human start dose and assessment of the need for human DDI studies.
Computational Scientist II LancesoftComputational Scientist IISouth San Francisco, CA$45Prior exposure to LLM applications is a big plus whether through building and deploying LLM-powered pipelines, working with agentic frameworks such as LangSmith, retrieval-augmented generation (RAG) architectures, harness engineering or guardrail design, or integrating LLM APIs into functional tools. You will work at the interface of AI engineering and quantitative pharmacology, partnering closely with M&S Scientists and Clinical Pharmacologists to develop tools that are scientifically grounded, reliable, and impactful.
Vice President, Translational Research Revolution Medicines IncVice President, Translational ResearchRedwood City, CA$294,000–$367,000 / yearThe Opportunity: As a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines'' discovery and development portfolio. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Vice President, Translational Research Revolution MedicinesVice President, Translational ResearchRedwood City, CaliforniaAs a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines' discovery and development portfolio. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Scientific Director, Computational Chemistry Neurocrine Biosciences IncScientific Director, Computational ChemistrySan Diego, CA$218,200–$298,000 / yearThe company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Working within multidisciplinary teams of medicinal chemists, structural biologists, pharmacologists, data scientists, and ADME/Tox representatives, provides molecular-level insight and computational expertise to inform compound design, potency and selectivity optimization, and de-risk design hypotheses.
Computational Scientist II Dawar ConsultingComputational Scientist IISouth San Francisco, CaliforniaYou will collaborate with scientists, pharmacometricians, and AI engineers to build production -ready AI solutions, develop evaluation frameworks, integrate scientific knowledge into AI systems, and improve the efficiency of quantitative drug development. Bachelor's degree with 5+ years of experience, or Master's/PhD in Computer Science, Data Science, Bioinformatics, Computational Biology, Pharmaceutical Sciences, or a related quantitative field.